Prior Agenda
(Oncology - December 2023)
TUESDAY, DECEMBER 5, 2023
All Times are PST Time Zone
8:30am // REGISTRATION AND BREAKFAST
9:00am // OPENING REMARKS
9:10am // KEYNOTE TALK - Dr. Alfred Slanetz, Chairman of the National Foundation for Cancer Research, Former CEO of Bluebird Bio, and CEO of Geneius Biotechnology TOPIC: Cellular Therapies
9:40am // Corporate Presentation - Geneius Biotechnology
9:55am // Corporate Presentation - Jaguar Health (NAS: JAGX)
10:10am // Corporate Presentation - Imagion Biosystems (ASX:IBX)
10:25am // Corporate Presentation - Calviri
10:40am // Corporate Presentation - SciTech Development
10:55am // Corporate Presentation - Nuclera
11:10am // Corporate Presentation - Pacylex Pharmaceuticals
11:25am // Corporate Presentation - CureLab Oncology
11:40am // Corporate Presentation - Osmol Therapeutics
11:55am // Corporate Presentation - TibaRay
12:10pm // INVESTOR PANEL DISCUSSION. Moderator: William Werkmeister, Partner, MedInvest. Panelists: Mitchell Mutz, Entrepreneur Partner, Vivo Capital | Satoshi Konagai, Senior Investment Manager, Astellas Venture Management, Christiana Bardon, Co-Managing Partner, MPM Capital | Lusong Luo, SVP, External Innovation, BeiGene
12:50pm // LUNCH BREAK / NCI Talk
1:05pm // SPEAKER - Dr. Michael Salgaller, Supervisor, Technology Analysis and Marketing Unit (TAMU), NCI/NIH. Topic: Beyond SBIRs: Leveraging the NIH to Improve Pipelines and Bottom Lines
1:35pm // Corporate Presentation - Processa Pharmaceuticals (Nasdaq: PCSA)
1:50pm // Corporate Presentation - HAWK Biosystems
2:05pm // Corporate Presentation - Peel Therapeutics
2:20pm // Corporate Presentation - Focal Medical
2:35pm // Corporate Presentation - AevisBio
2:50pm // Corporate Presentation - Pleco Therapeutics
3:05pm // Corporate Presentation - M.T.3 USA
3:20pm // Corporate Presentation - AIVITA Biomedical
3:35pm // Corporate Presentation - GT Medical Technologies
3:50pm // Corporate Presentation - TAE Life Sciences
4:05pm // Corporate Presentation - OncoGenesis
4:20pm // Corporate Presentation - Adovate
4:35pm // Corporate Presentation - ImpriMed
4:50pm // Corporate Presentation - Immunova
5:05pm // Corporate Presentation - EMulate Therapeutics
5:20pm // SPEAKER - Josh Seidenfeld, Partner, Cooley. TOPIC: Venture Financing and Structuring
5:50pm // CLOSING REMARKS
6:00pm // RECEPTION
WEDNESDAY, DECEMBER 6, 2023
All Times are PST Time Zone
8:30am // REGISTRATION AND BREAKFAST
9:00am // OPENING REMARKS
9:10am // KEYNOTE TALK - Dr. Howard Chang, Professor Genetics and Dermatology at Stanford. TOPIC: Clonal Replacement of Tumor-Specific T-cells following PD-1 Blockade
9:40am // Corporate Presentation - Inimmune Corp
9:55am // Corporate Presentation - Sirnaomics (2257.HK)
10:10am // Corporate Presentation - Apricity Health
10:25am // Corporate Presentation - GenEndeavor
10:40am // Corporate Presentation - LifeBridge Innovations
10:55pm // KEYNOTE TALK - Dr. Crystal Mackall, Founding Director, Stanford Center for Cancer Cell Therapy | Director, Parker Institute for Cancer Immunotherapy at Stanford. TOPIC: Pediatric Immuno-Oncology
11:25am // Corporate Presentation - FYR Diagnostics
11:40am // Corporate Presentation - Attivare Therapeutics
11:55am // Corporate Presentation - SageMedic
12:10pm // Corporate Presentation - Genomate Health
12:25pm // Corporate Presentation - Circle Pharma
12:40pm // Corporate Presentation - Nanocan Therapeutics
12:55pm // LUNCH BREAK / NCI Talk
1:10pm // SPEAKER - Dr. Michael Salgaller, Supervisor, Technology Analysis and Marketing Unit (TAMU), NCI/NIH. Topic: NIH as Your Technology Development and Commercialization Partner
1:40pm // Corporate Presentation - 7 Hills Pharma
1:55pm // Corporate Presentation - Azkarra Therapeutics
2:10pm // Corporate Presentation - iSono Health
2:25pm // Corporate Presentation - Qureator
2:40pm // SPEAKER - Dr. Dean W. Felsher, Professor and Associate Chief of Medicine-Oncology and Pathology, Standford MEDICINE. Topic: Oncogenes are the Key Targets to Both Reverse Cancer and Restore Immunity
3:10pm // SPEAKER - Marya Postner, Partner, Cooley. TOPIC: Structuring Licensing and Partnering Deals
3:40pm // CLOSING REMARKS
3:50pm // RECEPTION